Background To evaluate the efficacy and safety of injection bivalirudin made in China with heparin in the treatment atrial septal defect of congenital heart diseases interventional occluder.Methods Thirty-two atrial septal defect patients were divided into first experimental group treated with bivalirudin and standard group with heparin during operation,according to sequence with randomized and double-blind method.9 patients with thrombopenia,heparin allergy and renal insufficiency were included as second experimental group treated with bivalirudin in the operation.Observation indexes were ambulatory monitoring of activated clotting time (ACT),bleeding complications and postoperative transthoracic echocardiography.